Analysts at Bloomberg looked at price changes for Medicare’s Part D program for over 2000 drugs from 2013 through 2017. (Bloomberg Analysis) The median price increase per dose was 28%, with a very wide range and a lot of drugs in the 100% plus area. 22 drugs experienced 500% or greater price growth in that period. Under Part D’s current benefit design, that can be a real inhibitor for patients, as the more drug spending they have, the higher their out-of-pocket costs are likely to be. In total Medicare spent about $154.8 billion on Part D in 2017 and saw an average 10.6% spending increase annually from 2013 to 2017. Just 77 drugs accounted for half of total spending in 2017. Some drug makers are utilizing what at best might be described as unusual pricing behavior, for example, Thiola, used for a recurring kidney stone disease, had a 2400% price increase per dose, from $1.21 to $29.17. That might more accurately be referred to as rapacious pricing behavior. The company said the price hadn’t increased for three years (and? so what) and claimed it was “investing” in the product. Load of crap. Interestingly, a competitor to this product had the second-highest increase. Hmmm, where are the antitrust investigators, or is it just me who thinks this could be suggestive of collusion. Even generics weren’t immune. Generic sodium acetate, while admittedly still cheap, went from one cent a dose to six cents. How do you explain that? Congress is investigating all kinds of supposed fixes for drug pricing. The obvious one is what I keep beating the drum for–drug pricing is solely dependent on a government-granted monopoly; so the government should attach pricing constraints to those monopolies.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Two health care firms owned by private equity firms are merging in a transaction supposedly valued at $3 billion. HealthComp administers self-funded plans for employers and other groups and Virgin...
September 27, 2023
NextGen, an electronic medical records firm, is being put out of its public company misery, as a PE firm will pay $1.6 billion for the one-time high-flier.
September 7, 2023
A number of companies which attracted large financing rounds during the epidemic have imploded when reality set in. The latest is Cano Health, which is a little surprising since it...
August 15, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace